A closer look at aerosolized colistin

Clinical Infectious Diseases

Volumn 52, Issue 12, 2011, Pages 1472-1473

  Van Leeuwen, Dirk Harmen J ^a  

^a Location Alkmaar   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ADD ON THERAPY; AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY FAILURE; LETTER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; COLISTIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 79958125265     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir248     Document Type: Letter

References (2)

1. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: A matched case-control study. Clin Infect Dis 2010; 51:1238-44.
2. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22:535-43.